BI
Bioxytran, Inc.
BIXT · OTC
$0.02 -2.55% (-$0.00)
1M -1.12%
Market Cap $2.21M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.01
56.3% downside
Current Price
$0.023
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BIXT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
-
N/A P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 433.04%
ROE N/A
ROA N/A
Debt
0 /100
High Current ratio 0.00x
Int. coverage -19.09x
Debt/Equity N/A
Stability
17 /100
Unstable Beta 1.88x
EPS volatility 51.55%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BIXT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Platt
Employees
2
Headquarters
Needham